156 related articles for article (PubMed ID: 36440691)
1. Dupilumab as a novel therapy for bullous pemphigoid.
Zhang X; Man X; Tang Z; Dai R; Shen Y
Int J Dermatol; 2023 Apr; 62(4):e263-e266. PubMed ID: 36440691
[No Abstract] [Full Text] [Related]
2. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
Front Immunol; 2020; 11():611549. PubMed ID: 33584689
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.
Saleh M; Reedy M; Torok H; Weaver J
Dermatol Online J; 2021 Apr; 27(4):. PubMed ID: 33999579
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
Klepper EM; Robinson HN
Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
[TBL] [Abstract][Full Text] [Related]
5. Case report: Dupilumab for the treatment of bullous pemphigoid.
Wang M; Wang J; Shi B
Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.
Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C
Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201
[No Abstract] [Full Text] [Related]
7. A severe case of IgA bullous pemphigoid successfully treated with dupilumab.
Valenti M; De Giacomo P; Lavecchia A; Valenti G
Dermatol Ther; 2022 Nov; 35(11):e15890. PubMed ID: 36181411
[No Abstract] [Full Text] [Related]
8. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem.
Mutton T; Bocchi C; Gaban A; Marzola E; Schettini N; Borghi A
Ital J Dermatol Venerol; 2024 Jun; 159(3):361-363. PubMed ID: 38695597
[No Abstract] [Full Text] [Related]
9. Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid.
Wang Q; Ruan Y; Guo F; Zhu H; Pan M
Acta Derm Venereol; 2023 Sep; 103():adv12324. PubMed ID: 37707294
[No Abstract] [Full Text] [Related]
10. The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China.
Qi W; Rushan X
Int Immunopharmacol; 2023 May; 118():110050. PubMed ID: 37003187
[TBL] [Abstract][Full Text] [Related]
11. The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab.
Li W; Cai S; Man X
Dermatol Ther; 2022 Feb; 35(2):e15243. PubMed ID: 34854196
[No Abstract] [Full Text] [Related]
12. Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Wang SH; Zuo YG
Front Immunol; 2021; 12():800609. PubMed ID: 34887875
[No Abstract] [Full Text] [Related]
13. Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report.
Pop SR; Strock D; Smith RJ
Dermatol Ther; 2022 Aug; 35(8):e15623. PubMed ID: 35669992
[No Abstract] [Full Text] [Related]
14. Severe pemphigoid nodularis successfully treated with dupilumab.
Jendoubi F; Bost C; Tournier E; Paul C; Konstantinou MP
Dermatol Ther; 2022 Sep; 35(9):e15727. PubMed ID: 35861645
[No Abstract] [Full Text] [Related]
15. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic response of peripheral blood mononuclear cells to dupilumab in a 65-year-old patient with bullous pemphigoid.
Li ML; Hong YK; Lin YC; Natsuga K; Ujiie H; Izumi K; Iwata H; Hsu CK
Clin Exp Dermatol; 2023 Dec; 49(1):73-74. PubMed ID: 37650504
[No Abstract] [Full Text] [Related]
17. Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.
Learned C; Cohen SR; Cunningham K; Alsukait S; Santiago S; Lu J; Rothe M; Nichols A; Rosmarin D
J Am Acad Dermatol; 2023 Aug; 89(2):378-382. PubMed ID: 37115111
[No Abstract] [Full Text] [Related]
18. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
Front Immunol; 2021; 12():738907. PubMed ID: 34721404
[TBL] [Abstract][Full Text] [Related]
19. A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab.
Shan Y; Zuo YG
Dermatol Ther; 2022 Apr; 35(4):e15330. PubMed ID: 35080079
[No Abstract] [Full Text] [Related]
20. Reply to: 'Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab' by Baffa et al.
Sun L; Brazão C; Mancha D; Soares-de-Almeida L; Filipe P
J Eur Acad Dermatol Venereol; 2023 May; 37(5):e578-e580. PubMed ID: 36681888
[No Abstract] [Full Text] [Related]
[Next] [New Search]